PTC Therapeutics, Inc. Increase (Decrease) in Operating Liabilities
PTC Therapeutics, Inc. (PTCT) reported Increase (Decrease) in Operating Liabilities of -$1.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLiabilities · last filed 2026-02-19
- PTC Therapeutics, Inc. increase (decrease) in operating liabilities for the quarter ending 2024-12-31 was -$10.28M.
- PTC Therapeutics, Inc. increase (decrease) in operating liabilities for the quarter ending 2024-09-30 was $0.00.
- PTC Therapeutics, Inc. increase (decrease) in operating liabilities for fiscal 2025 was -$1.04M.
- PTC Therapeutics, Inc. increase (decrease) in operating liabilities for fiscal 2024 was -$44.18M.
| Period end | Increase (Decrease) in Operating Liabilities 3 month | Increase (Decrease) in Operating Liabilities 6 month | Increase (Decrease) in Operating Liabilities 9 month | Increase (Decrease) in Operating Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$1.04M 10-K · filed 2026-02-19 | |||
| 2024-12-31 | -$10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$10.28M derived: sum of 2 quarters · filed 2026-02-19 | -$44.18M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$33.91M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | -$33.91M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |